Search
Now showing items 1-10 of 12
The Impact Of Jak1/Jak2 Inhibitor Ruxolitinib On The Spleen Size And Symptom Burden In Myeloproliferative Diseases
(Akad Doktorlar Yayınevi, 2016)
Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has ...
The Impact Of Iron Overload On Transplant-Related Complications And Prognosis Of Acute Leukemias
(Akad Doktorlar Yayınevi, 2016)
The impacts of serum iron parameters and/or radiological evidence of systemic iron overload on the prognosis of hematopoietic stem cell transplantation (HSCT) in acute leukemia are controversial. Unfortunately, some of the ...
Striking Promotion Of The In Vitro Myeloma Monoclonal Immunoglobulin Aggregation By Ankaferd Hemostat
(Akad Doktorlar Yayınevi, 2012)
Ankaferd Blood Stopper (ABS) is a novel topical hemostatic agent. ABS-induced formation of the protein network with vital erythroid aggregation covers the entire physiological hemostatic process. ABS has pleiotropic cellular, ...
The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
(Akad Doktorlar Yayınevi, 2012)
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose ...
Pediatric Chemotherapeutic Regimen (Bfm-95) is Superior for Overall Survival in Adult Acute Lymphoblastic Leukemia
(Akad Doktorlar Yayınevi, 2018)
Acute lymphoblastic leukemia (ALL) is a neoplastic disease characterized by clonal malignant proliferation of the lymphoid blast cells. The aim of this study is to compare chemotherapy, pediatric regimen BFM-95 protocol ...
Iron Overload Pattern in Multiple Myeloma at Diagnosis Its Important Clinical Associations
(Akad Doktorlar Yayınevi, 2014)
As a plasmaproliferative disorder, multiple myeloma (MM) is not expected to cause IO and actually there are no reports on this condition in MM. In this retrospective study, we evaluated serum iron test results in MM patients ...
Idelalisib At The Crossroads Of B-Cell Lymphoproliferative Disorders
(Akad Doktorlar Yayınevi, 2016)
Phosphatidylinositol 3-kinases (PI3Ks) are considered as lipid kinases that are very active in the pathobiology of lymphoproliferative disorders (LPDs). Idelalisib, a selective inhibitor of the delta isoform of PI3K, ...
Bone Marrow Iron Staining Is a Reliable Test For Elimination of Iron Deficiency Anemia Rather Than Its Diagnosis
(Akad Doktorlar Yayınevi, 2013)
Iron deficiency anemia (IDA) is the most frequent type of anemia. The use of biochemical markers is a challenging way of diagnosis in case of inflammation and functional iron deficiency. The role of bone marrow aspirate ...
Acute In Vitro Effects of Abs (Ankaferd Hemostat) on The Lymphoid Neoplastic Cells (B-Cll And Raji Tumor Cell Lines)
(Akad Doktorlar Yayınevi, 2014)
ABS (Ankaferd Hemostat) has emerged as a novel haemostatic agent of plant origin. Its ability to interact with entire proteins including cell surface receptors and/or blood proteins plus tissue proteins revealed novel ...
Generic Imatinib Mesylate Is As Effective As Original Glivec In The Clinical Management Of Cml
(Akad Doktorlar Yayınevi, 2015)
Unsustainable drug prices in chronic myeloid leukemia (CML) and cancer may be causing harm to patients. The aim of this multi-center study is to assess the efficacy of generic imatinib mesylate (IM) over Glivec in terms ...
